Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)
A Phase 3 International, Multicenter, Open-label Study to Evaluate the Safety and Immunogenicity of 9vHPV Vaccine Administered as 2-dose Regimen With Extended Dosing Intervals in 9- to 14-Year Old Boys and Girls Compared With a Standard 3-dose Regimen in 16- to 26-Year Old Women
Sponsor: Merck Sharp & Dohme LLC
This PHASE3 trial investigates Papillomavirus Infections and is currently ongoing. Merck Sharp & Dohme LLC leads this study, which shows 16 recorded versions since 2021 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting PHASE3
-
May 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE3
-
Dec 2024 — May 2025 [monthly]
Active Not Recruiting PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE3
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE3
▶ Show 11 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE3
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE3
-
Jun 2022 — Jan 2024 [monthly]
Active Not Recruiting PHASE3
-
Dec 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE3
-
Apr 2021 — May 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Feb 2021 — Apr 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .